Welcome to our dedicated page for Scholar Rock Holding news (Ticker: SRRK), a resource for investors and traders seeking the latest updates and insights on Scholar Rock Holding stock.
Scholar Rock Holding Corporation (SRRK) is a clinical-stage biopharmaceutical company pioneering targeted therapies that modulate growth factor activation in serious diseases. This page serves as the definitive source for official updates, including clinical trial progress, regulatory milestones, and strategic partnerships.
Investors and researchers will find curated news spanning SRRK's neuromuscular, oncology, and metabolic disorder pipelines. Content includes earnings reports, scientific presentations, and manufacturing updates—all essential for tracking the company's novel niche modulator platform.
Key focus areas include apitegromab in spinal muscular atrophy, obesity therapeutics, and fibrosis interventions. Updates are organized chronologically with clear sourcing to maintain transparency. Bookmark this page for streamlined access to SRRK's advancements in precision biologics.
Scholar Rock (NASDAQ: SRRK) has received FDA Priority Review for its Biologics License Application (BLA) for apitegromab, a first-in-class muscle-targeted treatment for Spinal Muscular Atrophy (SMA). The FDA has set a PDUFA date of September 22, 2025.
Additionally, the European Medicines Agency (EMA) has validated the Marketing Authorisation Application (MAA) for apitegromab. The submissions are supported by positive data from the Phase 3 SAPPHIRE trial, which demonstrated statistically significant and clinically meaningful motor function improvements in SMA patients receiving apitegromab alongside SMN-targeted treatments.
The company is preparing for commercial launch in the U.S. in 2025, followed by European launch in 2026. The FDA's priority review designation indicates potential significant improvement in treatment effectiveness for SMA patients.
Scholar Rock (NASDAQ: SRRK) announced new Phase 3 SAPPHIRE trial data for apitegromab, their investigational muscle-targeted therapy for Spinal Muscular Atrophy (SMA). The trial met its primary endpoint with statistically significant improvement in motor function, showing a mean difference of 1.8 points (p=0.0192) in Hammersmith Functional Motor Scale Expanded (HFMSE) versus placebo.
Key secondary endpoints revealed that 30.4% of patients receiving apitegromab achieved ≥3-point HFMSE improvement compared to 12.5% on placebo (p=0.0156). The treatment demonstrated consistent benefits across all subgroups and showed improvements in Revised Upper Limb Module (RULM) and WHO motor development milestones.
The drug was well-tolerated with no serious adverse events related to apitegromab, positioning it as a potential complementary therapy to existing SMN-targeted treatments.
Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company, has announced new employee inducement grants under its 2022 Inducement Equity Plan. The company has awarded equity grants to seven new employees, including:
- 65,027 shares as inducement stock options with an exercise price of $35.15
- 48,773 shares as inducement restricted stock units
The stock options will vest 25% after one year from each employee's start date, with the remaining 75% vesting in 12 quarterly installments. The restricted stock units will vest in four equal annual installments. These grants, totaling 113,800 shares, are designed to attract new talent and comply with Nasdaq Listing Rule 5635(c)(4).
Scholar Rock (NASDAQ: SRRK) reported its full year 2024 financial results, highlighting significant progress in its drug development pipeline. The company submitted a BLA for apitegromab in SMA patients and plans to submit an EU marketing application in Q1 2025, with US launch anticipated in Q4 2025.
Key financial metrics include a net loss of $246.3 million ($2.47 per share) for 2024, compared to $165.8 million in 2023. R&D expenses increased to $184.6 million, while G&A expenses rose to $67.5 million. The company ended 2024 with $437.3 million in cash and equivalents, expected to fund operations into Q4 2026.
Notable upcoming milestones include topline data from the Phase 2 EMBRAZE obesity trial in Q2 2025 and an IND application for SRK-439 in Q3 2025. The company also completed a $345 million public offering in October 2024 to support commercial launch preparations.
Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company specializing in treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and diseases involving protein growth factors, has announced its participation in four major investor conferences in March:
- TD Cowen 45th Annual Health Care Conference - March 4 in Boston (fireside chat at 2:30 p.m. ET)
- Wedbush Cardiometabolic Conference - March 10 in Miami (panel presentation at 10:05 a.m. ET)
- Jefferies Biotech on the Bay Summit - March 11 in Miami (1x1 meetings)
- BMO Obesity Summit - March 25 in New York City (panel presentation at 1:15 p.m. ET)
A live webcast of the Cowen presentation will be available on the company's investor website, with replay access for approximately 90 days.
Scholar Rock (NASDAQ: SRRK) announced it will present additional data from its Phase 3 SAPPHIRE clinical trial at the 2025 MDA Clinical & Scientific Conference in Dallas. The trial evaluated apitegromab, a muscle-targeted therapy for spinal muscular atrophy (SMA) patients receiving SMN-targeted treatments.
Following positive topline data in October 2024 and BLA submission to FDA in January 2025, Dr. Thomas O. Crawford from Johns Hopkins University will present detailed trial analysis through an oral presentation and poster on March 19th. Additionally, the company will present preclinical data combining apitegromab with a dystrophin corrector for Duchenne muscular dystrophy (DMD).
Scholar Rock (NASDAQ: SRRK) has granted inducement equity awards to eleven new employees, totaling 371,500 shares of common stock. The awards consist of inducement stock options for 212,284 shares and restricted stock units for 159,216 shares. The stock options have an exercise price of $38.14, matching the closing price on February 10, 2025.
These awards are part of the Company's 2022 Inducement Equity Plan, exclusively used for granting equity to new hires. The stock options will vest 25% after one year from each employee's start date, with the remaining 75% vesting in 12 quarterly installments. The restricted stock units will vest in four equal annual installments. All vesting is contingent on continued employment with Scholar Rock.
Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and other diseases involving protein growth factors, has scheduled a conference call for February 27, 2025, at 8:15am ET. The call will cover fourth quarter and full-year 2024 financial results along with a business update.
The company will provide multiple ways to access the call, including a live audio webcast available through the Investor Relations section of Scholar Rock's website. An archived replay will remain accessible on the website for approximately 90 days after the event.
Scholar Rock (SRRK) has submitted a Biologics License Application (BLA) to the FDA for apitegromab, a muscle-targeted therapy for Spinal Muscular Atrophy (SMA) patients. The submission is based on the successful Phase 3 SAPPHIRE trial, which demonstrated a statistically significant 1.8-point improvement in motor function compared to placebo at week 52, measured by the Hammersmith Functional Motor Scale-Expanded.
The company has received Fast Track, Orphan Drug, and Rare Pediatric Disease Designations from the FDA, and plans to submit a Marketing Authorisation Application to the European Medicines Agency in Q1 2025. Scholar Rock has requested Priority Review, which could reduce FDA review time to six months. Additionally, the company plans to initiate the Phase 2 OPAL trial in mid-2025 to study apitegromab in SMA patients under two years of age.
Scholar Rock (NASDAQ: SRRK) has appointed Lisa Wyman as Chief Technical and Quality Officer (CTQO) to support the company's transformation into a fully integrated biopharma company ahead of its first expected drug approval and commercial launch in 2025. Wyman brings over 20 years of leadership experience in technical and quality operations from her roles at Generate:Biomedicines and Acceleron Pharma.
As part of organizational restructuring, the Chief Operating Officer role is being eliminated. Ted Myles, current COO & CFO, will remain with the company through mid-March and serve as a Senior Advisor for six months during the transition. The company has initiated a search for a new CFO.
At her previous position as Chief Technical Operations Officer at Generate:Biomedicines, Wyman led global technical operations and CMC development. At Acceleron, she played a key role in transforming the company from an R&D-focused entity to an integrated biotech, contributing to its $11 billion acquisition by Merck & Co. in 2021.
FAQ
What is the current stock price of Scholar Rock Holding (SRRK)?
What is the market cap of Scholar Rock Holding (SRRK)?
